CO2019012143A2 - Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso - Google Patents
Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su usoInfo
- Publication number
- CO2019012143A2 CO2019012143A2 CONC2019/0012143A CO2019012143A CO2019012143A2 CO 2019012143 A2 CO2019012143 A2 CO 2019012143A2 CO 2019012143 A CO2019012143 A CO 2019012143A CO 2019012143 A2 CO2019012143 A2 CO 2019012143A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- programmed death
- death receptor
- combination
- stable formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
La invención se refiere a formulaciones estables que comprenden anticuerpos o fragmentos de fijación al antígeno de estos que se fijan al antígeno 4 asociado al linfocito T citotóxico (CTLA4), opcionalmente que además contienen un anticuerpo anti-receptor de muerte programada humano 1 (PD-1) o fragmento de fijación al antígeno de este. Además se proporcionan métodos para el tratamiento de diversos tipos de cáncer e infecciones crónicas con las formulaciones de la invención.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762500268P | 2017-05-02 | 2017-05-02 | |
PCT/US2018/030420 WO2018204343A1 (en) | 2017-05-02 | 2018-05-01 | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019012143A2 true CO2019012143A2 (es) | 2020-01-17 |
Family
ID=64016829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0012143A CO2019012143A2 (es) | 2017-05-02 | 2019-10-30 | Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso |
Country Status (16)
Country | Link |
---|---|
US (1) | US20200262922A1 (es) |
EP (1) | EP3618866A4 (es) |
JP (2) | JP2020518598A (es) |
KR (1) | KR102624564B1 (es) |
CN (1) | CN110678199A (es) |
AU (1) | AU2018263837A1 (es) |
BR (1) | BR112019022695A2 (es) |
CA (1) | CA3060695A1 (es) |
CL (1) | CL2019003143A1 (es) |
CO (1) | CO2019012143A2 (es) |
EA (1) | EA201992526A1 (es) |
MA (1) | MA50501A (es) |
MX (1) | MX2019013034A (es) |
SG (1) | SG11201910134SA (es) |
TN (1) | TN2019000294A1 (es) |
WO (1) | WO2018204343A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2170959T1 (sl) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
JP6992068B2 (ja) | 2016-12-07 | 2022-02-03 | アジェナス インコーポレイテッド | 抗ctla-4抗体およびそれらの使用方法 |
JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
SG11201909955XA (en) | 2017-05-02 | 2019-11-28 | Merck Sharp & Dohme | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
WO2019160755A1 (en) * | 2018-02-13 | 2019-08-22 | Merck Sharp & Dohme Corp. | Methods for treating cancer with anti pd-1 antibodies and anti ctla4 antibodies |
EP3876978A4 (en) * | 2018-11-07 | 2022-09-28 | Merck Sharp & Dohme Corp. | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (MP-1) ANTIBODIES AND THEIR METHODS OF USE |
MX2022003432A (es) * | 2019-09-23 | 2022-04-19 | Merck Sharp & Dohme Llc | Metodos y composiciones que comprenden un anticuerpo monoclonal antictla4 con proteinas de celulas hospederas reducidas y estabilidad del polisorbato-80 aumentada. |
KR20220149740A (ko) * | 2020-03-05 | 2022-11-08 | 머크 샤프 앤드 돔 엘엘씨 | Pd-1 길항제, ctla4 길항제 및 렌바티닙 또는 그의 제약상 허용되는 염의 조합물을 사용하여 암을 치료하는 방법 |
WO2022010988A1 (en) * | 2020-07-08 | 2022-01-13 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ctla-4 antibodies |
MX2023005345A (es) * | 2020-11-10 | 2023-05-22 | Sanofi Sa | Formulacion del conjugado anticuerpo-farmaco para ceacam5. |
WO2023211868A1 (en) * | 2022-04-29 | 2023-11-02 | Merck Sharp & Dohme Llc | Stable formulations of anti-ilt4 antibodies or antigen-binding fragments thererof in combination with anti-pd-1 antibodies and methods of use thereof |
WO2024025986A1 (en) * | 2022-07-28 | 2024-02-01 | Merck Sharp & Dohme Llc | Pharmaceutical compositions of programmed death receptor 1 (pd-1) antibodies and ph20 variants or fragments thereof |
WO2024025989A1 (en) * | 2022-07-28 | 2024-02-01 | Merck Sharp & Dohme Llc | Pharmaceutical compositions of programmed death receptor 1 (pd-1) antibodies and rhuph20 or variants or fragments thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006096488A2 (en) * | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | Composition comprising human igg2 antibody and chelating agent |
AU2006244885B2 (en) * | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
EP2442798A4 (en) * | 2009-06-18 | 2013-03-13 | Wyeth Llc | LYOPHILIZED FORMULATIONS FOR SMALL-SCALE MODULAR IMMUNOPHARMACEUTICAL AGENTS |
CN105296433B (zh) * | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
LT3283107T (lt) * | 2015-04-17 | 2020-09-10 | Bristol-Myers Squibb Company | Kompozicija apimanti ipilimumabo ir nivolumabo kombinaciją |
US9995753B2 (en) * | 2015-09-25 | 2018-06-12 | Merck Sharp & Dohme Corp. | Anti-pembrolizumab antibodies |
-
2018
- 2018-05-01 MX MX2019013034A patent/MX2019013034A/es unknown
- 2018-05-01 KR KR1020197035373A patent/KR102624564B1/ko active IP Right Grant
- 2018-05-01 TN TNP/2019/000294A patent/TN2019000294A1/en unknown
- 2018-05-01 EA EA201992526A patent/EA201992526A1/ru unknown
- 2018-05-01 EP EP18793916.0A patent/EP3618866A4/en active Pending
- 2018-05-01 BR BR112019022695-8A patent/BR112019022695A2/pt unknown
- 2018-05-01 MA MA050501A patent/MA50501A/fr unknown
- 2018-05-01 SG SG11201910134S patent/SG11201910134SA/en unknown
- 2018-05-01 CA CA3060695A patent/CA3060695A1/en active Pending
- 2018-05-01 AU AU2018263837A patent/AU2018263837A1/en active Pending
- 2018-05-01 US US16/609,671 patent/US20200262922A1/en active Pending
- 2018-05-01 CN CN201880029175.1A patent/CN110678199A/zh active Pending
- 2018-05-01 JP JP2019559826A patent/JP2020518598A/ja active Pending
- 2018-05-01 WO PCT/US2018/030420 patent/WO2018204343A1/en active Application Filing
-
2019
- 2019-10-30 CO CONC2019/0012143A patent/CO2019012143A2/es unknown
- 2019-10-30 CL CL2019003143A patent/CL2019003143A1/es unknown
-
2023
- 2023-05-24 JP JP2023085581A patent/JP2023109942A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112019022695A2 (pt) | 2020-05-26 |
SG11201910134SA (en) | 2019-11-28 |
CL2019003143A1 (es) | 2020-03-20 |
MA50501A (fr) | 2020-09-09 |
EP3618866A1 (en) | 2020-03-11 |
US20200262922A1 (en) | 2020-08-20 |
WO2018204343A1 (en) | 2018-11-08 |
EP3618866A4 (en) | 2021-07-14 |
CN110678199A (zh) | 2020-01-10 |
MX2019013034A (es) | 2020-02-05 |
CA3060695A1 (en) | 2018-11-08 |
JP2020518598A (ja) | 2020-06-25 |
EA201992526A1 (ru) | 2020-03-13 |
AU2018263837A1 (en) | 2019-12-05 |
TN2019000294A1 (en) | 2021-05-07 |
JP2023109942A (ja) | 2023-08-08 |
KR20190142393A (ko) | 2019-12-26 |
KR102624564B1 (ko) | 2024-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019012143A2 (es) | Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
CO2019012356A2 (es) | Formulaciones estables de anticuerpos anti-tigit solos y en combinación con anticuerpos receptores de muerte programada 1 (pd-1) y métodos para su uso | |
CL2017001866A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
CL2019003093A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. | |
PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
CL2023001092A1 (es) | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor | |
CL2018000744A1 (es) | Anticuerpos anti-tigit (inmunoreceptor de linfocitos t con dominios ig e itim) y metodos de uso. | |
MX2017015811A (es) | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). | |
CL2020000263A1 (es) | Conjugado de anticuerpo monoclonal contra bcma-fármaco. | |
CL2017000250A1 (es) | Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso | |
EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
EA201891066A1 (ru) | Антитела к ror1 | |
CL2019001740A1 (es) | Novedoso conjugado de amanitina. | |
CL2016002585A1 (es) | Inmunoconjugado que comprende una proteína de unión a antígeno que se une a antígeno de maduración de linfocitos b (bcma) y un agente citotóxico, composición farmacéutica y su uso (divisional solicitud 201303373) | |
MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
EA201792273A1 (ru) | Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела | |
MX2017006323A (es) | Anticuerpos que comprenden regiones constantes pesadas modificadas. | |
PE20091196A1 (es) | Anticuerpos contra el vegf completamente humano, composiciones y metodos | |
CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
PE20160690A1 (es) | Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos | |
BR112019001206A2 (pt) | anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss) | |
PH12020552115A1 (en) | Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies | |
PE20191487A1 (es) | Anticuerpos anti-gitr y metodos de uso de los mismos | |
CO2020013833A2 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso |